Potential therapeutic use of antibodies directed towards HuIFN-γ

Biotherapy

Volumn 10, Issue 1, 1997, Pages 49-57

  Froyen, Guy ^a   Billiau, Alfons ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Human antibodies; Immunogenicity; Immunotherapy; Interferon gamma

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; INTERFERON ANTIBODY; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; AUTOIMMUNITY; CACHEXIA; CANCER; DIABETES MELLITUS; DRUG ACTIVITY; DRUG RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN FRAGMENTS; INTERFERON TYPE II; MICE;

EID: 0030809460     PISSN: 0921299X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02678217     Document Type: Article

References (103)

1. Finbloom DS, Wahl LM, Winestock KD. The receptor of interferonγ on human peripheral blood monocytes consists of muntiple distinct units. J Biol Chem 1991; 266: 22545-22548.
2. Taniguchi T. Cytokine signalling through nonreceptor protein tyrosine kinases. Science 1995; 268: 251-255.
3. Dijkmans R, Billiau A. Interferonγ: a master key in the immune system. Curr Opin Biol 1988; 1: 269-274.
4. Froyen G, Heremans H, Dijkmans R, Billiau A. Apparent auto- inhibition of murine interferonγ due to a serum component. In: Cantell K, Schellekens H, eds. The Biology of the Interferon System. Martinus Nijhoff Publishers, 1986:45-50.
5. Turano A, Balsari A, Viani E, Landolfo S, Zanoni L, Gargiulo F, Caruso A. Natural human antibodies to 7 Interferon interfere with the immunomodulating activity of the lymphokine. Proc Nad Acad Sci USA 1992; 89:4447-4451.
6. Hamilton RG. Monoclonal antibodies in the diagnosis and treatment of human diseases. Ann Biol Clin 1989; 47: 575581.
7. Waldmann T. Monoclonal antibodies in diagnosis and therapy. Science 1991; 252: 1657-1662.
8. Heremans H, Dijkmans R, Sobis H, Vandekerckhove F, Billiau A. Regulation by interferons of the local inflammatory response to bacterial lipopolysaccharide. J Immunol 1987; 138: 4175-4179.
9. Billiau A, Heremans H, Vandekerckhove F, Dillen C. Anti-interferon 7 antibody protects mice against the generalized Shwartzman reaction. Eur J Immunol 1987; 17: 1851-1854.
10. Heremans H, Van Damme J, Dillen C, Dijkmans R, Billiau A. Interferonγ, a mediator of lethal lipopolysaccharide-induced Shwartzman-like shock reactions in mice. J Exp Med 1990; 171: 1853-1869.
11. Geiger K, Howes E, Gallina M, Huang XI, Travis GH, Sarvetnick N. Transgenic mice expressing IFN-gamma in the retina develop inflammation of the eye and photoreceptor loss. Invest Opthalmol Vis Sci 1994; 35: 2667-2681.
12. Matthys P, Dillen C, Proost P, Heremans H, Van Damme J, Billiau A. Modification of the anti-CDS-induced cytokine release syndrome by anti-interferonγ or anti-interleukin-6 antibody treatment: protective effects of biphasic changes in blood cytokine levels. Eur J Immunol 1993; 23: 2209-2216.
13. Matthys P, Mitera T, Heremans H, Van Damme J, Billiau A. Anti-gamma Interferon and anti-interleukin-6 antibodies affect Staphylococcal enterotoxin B-induced weight loss, hypoglycemia, and cytokine release in D-galactosaminesensitized and unsensitized mice. Infect Immun 1995; 63: 1158-1164.
14. Jarpe MA, Hayes MP, Russell JK, Johnson HM, Russell SW. Causal association of interferonγ with tumor regression. J Interferon Res 1989; 9:239-244.
15. Prat M, Bretti S, Amedeo M, Landolfo S, Comoglio PM. Monoclonal antibodies against murine IFNγ abrogate in vivo tumor immunity against RSV-induced cytotoxic T lymphocyte differentiation. J Immunol 187; 138: 4530-4533.
16. Watanabe Y, Kuribayashi K, Miyatake S, Nishihara E, Nakayama E Taniyama T, Sakata TA. Endogenous expression of mouse Interferon 7 cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity and augmented anti-tumor immunity. Proc Natl Acad Sci USA 1989; 86: 9456-9460.
17. Ferrantini M, Giovarelli M, Modesti A, Musiani P, Modica A, Venditti M, Peretti E, Lollini P, Nanni P, Fomi G, Belardelli F. IFN-Q1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity: Comparative studies with IFN-gamma-producing TS/A cells. J Immunol 1994; 153: 4604-4615.
18. Matthys P, Heremans H, Opdenakker G, Billiau A. AntiIFNγ antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia. Eur J Cancer 1991 ; 27: 182-187.
19. Ramani P, Balkwill FR. Enhanced metastasis of a mouse carcinoma after in vitro treatment with interferonγ. Int J Cancer 1987; 40: 830-834.
20. Langstein HN, Doherty GM, Fraker DL, Buresh CM, Norton JA. The roles of 7-interferon and tumor necrosis factor in an experimental rat model of cancer cachexia. Cancer Research 1991; 51:2302-2306.
21. Matthys P, Dijkmans R, Proost P, Van Damme J, Heremans H, Sobis H, Billiau A. Severe cachexia in mice inoculated with interferonγ-producing cells. Int J Cancer 1991; 49: 77-82.
22. Duong TT, St Louis J, Gilbert JJ, Finkelman FD, Strejan GH. Effect of anti-interferonγ and anti-interleukin-2 monoclonal antibody treatment on the development of actively and passively induced experimental allergic encephalomyelitis in the SJL/J mouse. J Neuroimmunol 1992; 36: 105-115.
23. Billiau A, Heremans H, Vandekerckhove F, Dijkmans R, Sobis H, Meulepas E, Carton H. Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma. J Immunol 1988; 140: 1506-1510.
24. Hirsch RL, Panitch HS, Johnson KP. Lymphocytes from multiple sclerosis patients produce elevated levels of gamma interferon in vitro. J Clin Immunol 1985; 5: 386-389.
25. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: Do cytokines trigger off exacerbations? Acta Neurol Scand 1988; 78: 318-323.
26. Panitch HS, Haley AS, Hirsch RL, Johnson KP, Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987; i: 893-895.
27. Vass K, Heininger K, Schäfer B, Linington C, Lassman H. Interferonγ potentiates antibody-mediated demyelination in vivo. Ann Neurol 1992; 32:198-206.
28. Jacob CO, Van der Meide PH, McDevitt HO. In vivo treatment of (NZB x NZW)F1 lupus-like nephritis with monoclonal antibody to 7 interferon. J Exp Med 1987; 166: 798-803.
29. Ozmen L, Roman D, Fountoulakis M, Schmid G, Ryffel B, Garotta G. Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon 7 receptor inhibits the onset of glomerulonephritis. Eur J Immunol 1995; 25: 6-12.
30. Fountoulakis M, Schlaeger E, Gentz R, Juranville J, Manneberg M, Ozmen L, Garotta G. Purification and biological characterization of a soluble mouse interferonγ receptor produced in insect cells. Eur J Biochem 1991; 198: 441-450.
31. Machold KP, Smolen JS. Interferonγ-induced exacerbation of systemic lupus erythematosus. JRheumatol 1990; 17:831832.
32. Braude IA, Hochberg MC, Amett FC, Waldmann TA. In vitro suppression of ami-DNA antibody and immunoglobulin synthesis in systemic lupus erythematosus patients by gamma interferon. J Rheumatol 1988; 15: 438-444.
33. Graninger WB, Hassfeld W, Pesau BB, Machold KP, Zielinski CC, Smolen JS. Induction of systemic lupus erythematosus by interferonγ in a patient with rheumatoid arthritis. J Rheumatol 1991; 18: 1621-1622.
34. Jacob CO, Holoshitz J, Van der Meide P, Strober S, McDevitt NO. Heterogeneous effect of flFN^y in adjuvant arthritis. J Immunol 1989; 142: 1500-1505.
35. Mauritz NJ, Holmdahl R, Jonsson R, Van der Meide PH, Scheynius A, Klareskog L. Treatment with gamma-interferon triggers the onset of collagen arthritis in mice. Arthritis Rheum 1988; 31: 1297-1304.
36. Nakajima H, Takamori H, Hiyama Y, Tsukuda W. The effect of treatment with interferon-gamma on type II collageninduced arthritis. Clin Exp Immunol 1990; 81: 441-445.
37. Machold KP, Neumann K, Smolen JS. Recombinant human interferon 7 in the treatment of rheumatoid arthritis: double blind placebo controlled study. Ann Rheum Dis 1992; 51: 1039-1043.
38. Cannon GW, Emkey RD, Denes A, Cohen SA, Saway PA, Wolfe F, Jaffer AM, Weaver AL, Cogen L, Gulinello J, Kennedy SM, Schindler JD. Prospective two-year followup of recombinant interferonγ in rheumatoid arthritis. J Rheumatol 1990; 17: 304-310.
39. Campbell IL, Oxbrow L, Koulmanda M, Harrison LC. IFNγ induces islet cell MHC antigens and enhance autoimmune, streptozotocin-induced diabetes in the mouse. J Immunol 1988; 140: 1111-1116.
40. Campbell IL, Kay TWH, Oxbrow L, Harrison LC. Essential role for interferonγ and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J Clin Invest 1991; 87:739γ42.
41. Kay TWH, Campbell IL, Oxbrow L, Harrison LC. Overexpression of class I major histocompatibility complex accompanies insulitis in the non-obese diabetic mouse and is pre-vented by anti-interferonγ antibody. Diabetologia 1991; 34: 779γ85.
42. Sarvetnick N, Shizuru J, Liggitt L, Mclntyre B, Gregory A, Parslow T, Stewart T. Loss of pancreatic islet tolerance induced by beta-cell expression of interferon-gamma. Nature 1990; 346: 844-847.
43. Wogensen L, Molony L, Gu D, Krahl T, Zhu S, Sarvetnick N. Postnatal interferon-gamma treatment prevents pancreatic inflammation in transgenic mice with beta-cell expression of interferon-gamma. J Interferon Res 1994; 14: 111-116.
44. Rémy J-J, Salamero J, Michel-Bechet M, Charreire J. Experimental autoimmune thyroiditis induced by recombinant interferonγ. Immunol Today 1987; 8: 73.
45. Kawakami Y, Kuzuya N, Watanabe T, Uchiyama Y, Yamashita K. Induction of experimental thyroiditis in mice by recombinant Interferon 7 administration. Acta Endocrinol 1990; 122: 41-48.
46. Toyonaga T, Hino O, Sugai S, Wakasugi S, Abe K, Shichiri M, Yamamura K. Chronic active hepatitis in transgenic mice expressing interferon-gamma in the liver. Proc Natl Acad Sci USA 1994; 91: 614-618.
47. Barker JNW, Alle MH, MacDonald DM. Alterations induced in normal human skin by in vivo interferon-gamma. Brit J Dermatol 1993; 122: 451-458.
48. Fierlbeck G, Rassner G. Treatment of psoriasis and psoriaric arthritis with interferon gamma. J Invest Dermatol 1990; 95: 138S-141S.
49. Kaneko F, Suzuki M, Taniguchi Y, Itoh N, Minagawa, T. Immunohistopathologic studies in the development of psoriatic lesion influenced by gamma-interferon and the producing cells. J Dermatol Science 1990; 1; 425-434.
50. Gu D, Wogensen L, Calcutt NA, Xia C, Zhu S, Merlie JP, Fox HS, Lindstrom J, Powell HC, Sarvetnick N. Myastenia Gravis-like syndrome induced by expression of interferon gamma in neuromuscular junction. J Exp Med 1995; 181: 547-557.
51. Landolfo S, Cofano F, Giovarelli M, Prat M, Cavallo G, Fomi G. Inhibition of interferon-gamma may suppress allograft reactivity by T lymphocytes in vitro and in vivo. Science 1985; 229: 176-179.
52. Rosenberg AS, Finbloom DS, Maniera TG, Van der Meide PH, Singer A. Specific prolongation of MHC class II disparate skin allografts by in vivo administration of anti-IFNγ monoclonal antibody. J Immunol 1990; 144: 4648-4650.
53. Mowat A. Antibodies to IFNγ prevent immunologically mediated intestinal damage in murine graft-versus-host reaction. Immunology 1989; 68: 18-23.
54. Brok HPM, Heidt PJ, Van der Meide PH, Zürcher C, Vossen J. Interferonγ prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Immunol 1993; 151: 6451-6459.
55. Glassy MC, Handley HH, Sum CD, Royston I. Genetically stable human hybridomas secreting tumor reactive human monoclonal IgM. Cancer Invest 1987; 5: 447-455.
56. Albright JF, Janicki B, Scharff MD. Generation and maintenance of hybridomas. Immunol Today 1987; 8: 256-257.
57. James K, Bell BT. Human monoclonal antibody production. Current status and future prospects. J Immunol Methods 1987; 100: 5-40.
58. Koda K, Glassy MC. In-vitro immunization for the production of human monoclonal antibody. Hum Antib Hybridomas 1990; 1: 15-22.
59. BorrebaeckCAK. Human mAbs produced by primary in-vitro immunization. Immunol Today 1988; 9: 355-359.
60. McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, Weissman IL. The SCID-hu mouse: Murine model for the analysis of human hematolymphoid differentiation and function. Science 1988; 241: 1632-1639.
61. Mosier DE, Gulizia RJ, Baird SM, Wilson DB. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 1988; 335: 256-259.
62. Hoogenboom HR, Marks JD, Griffiths AD, Winter G. Building antibodies from their genes. Immunol Rev 1992; 130: 41-68.
63. Boulianne GL, Hozumi N, Shulman MJ. Production of functional chimaeric mouse/human antibody. Nature 1984; 312: 643-646.
64. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimaeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984; 81: 6851-6855.
65. Jones PT, DearPH, Foote J, NeubergerMS, WinterG. Replacing the complementarity-determining regions in human antibody with those from a mouse. Nature 1986; 321: 522-525.
66. Pimm MV, Durrant LG, Baldwin RW. The influence of syngeneic anti-idiotypic antibody on the biodistribution of an anti-tumour monoclonal antibody in BALB/c mice. Int J Cancer 1986; 43: 147-151.
67. BrUggemann M, Winter G, Waldmann H, Neuberger MS. The immunogenicity of chimeric antibodies. J Exp Med 1989; 170: 2153-2157.
68. LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 1989; 86: 4220-4224.
69. Knox SJ, Levy R, Hodgkinson S, Bell R, Brown S, Wood GS, Hoppe R, Abel, E.A., Steinman, L., Berger, R.G., Gaiser, C, Young, G., Bindl, J., Hanham A, Reichert T. Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with Mycosis fungoides. Blood 1991; 77: 20-30.
70. Hale G, Dyer MJS, Clark MR, Phillips JM, Marcus R, Riechmann L, Winter G, Waldmann H. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; ii: 1394-1399.
71. Mathieson PW, Cobbold SP, Hale G, Clark MR, Oliviera DBG, Lockwood CM, Waldmann H. Monoclonal antibody therapy in systemic vasculitis. New Engl J Med 1990; 323: 250-254.
72. Co MS, Queen C. Humanized antibodies for therapy. Nature 1991:351:501-502.
73. Caron PC, Schwanz MA, Co MS, Queen C, Finn RD, Graham MC, Divgi CR, Larson SM, Scheinberg DA. Murine and humanized constructs of monoclonal antibody M195 (antiCD33) for the therapy of acute myelogenous leukemia. Cancer 1994; 73: 1049-1056.
74. Neuberger MS, Williams GT, Fox RO. Recombinant antibodies possessing novel effector functions. Nature 1984; 312: 604-608.
75. Sharon J, Gefter ML, Manser T, Morrison SL, Oi VT, Ptashne M. Expression of a VHCK chimaeric protein in mouse myeloma cells. Nature 1984; 309: 364-367.
76. Riechmann L, Foote J, Winter G. Expression of an antibody Fv fragment in myeloma cells. J Mol Biol 1988; 203: 825828.
77. Skerra A, Plückthun A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coll. Science 1988; 240: 1038-1041.
78. Better M, Chang CP, Robinson RR, Horwitz AH. Escherichia coli secretion of an active chimeric antibody fragment. Science 1988; 240: 1041-1043.
79. Huston JS, Levinston D, Mudgett-Hunter M, Tai M-S, Novotny J, Margolies MM, Ridge RJ, Braccoleri RE, Haber E, Crea R, Oppermann H. Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin singlechain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 1988; 85: 5879-5883.
80. Bird RE, Hardraan KD, Jacobson JW, Johnson S, Kaufman BM, Lee S, Pope SH, Riordan OS, Whitlow M. Single-chain antigen-binding proteins. Science 1988; 242: 423-426.
81. Burton DR. Human and mouse monoclonal antibodies by repertoire cloning. Tibtech 1991; 9: 169-175.
82. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization. Human antibodies from V- gene libraries displayed on phage. J Mol Biol 1991; 222: 581-597.
83. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348: 552-554.
84. Huse WD, Sastry L, Iverson SA, Kang AS, Alting-Mees M., Burton DR, Benkovic SJ, Lerner RA. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 1989; 246: 1275-1281.
85. Hawkins RE, Winter G. Cell selection strategies for making antibodies from variable gene libraries: Trapping the memory pool. Eur J Immunol 1992; 22: 867-870.
86. Green LL, Hardy MC, Maynard-Currie CE, Tsuda H, Louie DM, Mendez MI, Abderrahim H, Noguchi M, Smith DH, Zeng Y, David NE, Sasai H, Garza D, Brenner DG, Hales JF, McGuinness RP, Capon DJ, Klapholz S, Jakobovits A. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nature Genetics 1994; 7: 13-21.
87. Duchosal MA, Eming SA, Fischer P, Lerurcq D, Barbas III CF, McConahey PJ, Caothien RH, Thomton GB, Dixon FJ, Burton DR. Immunization of hu-PBL-SCID mice and the rescue of human monoclonal Fab fragments through combinatorial libraries. Nature 1992; 355: 258-262.
88. Sandvig S, Laskay T, Andersson J, De Ley M, Andersson U. Gamma-interferon is produced by CD3+ and CD3- lymphocytes. Immunol Rev 1987; 97: 51-65.
89. Huston JS, McCartney J, Tai M-S, Mottola-Hartshom C, Jin D, Warren F, Keck P, Oppermann H. Medical applications of single-chain antibodies. Intern Rev Immunol 1993; 10: 195-217.
90. Bird RE, WebbWalker B. Single-chain antibody variable regions. Tibtech 1991; 9: 132-137.
91. Froyen G, Ronsse I, Billiau A. Bacterial expression of a single- chain antibody fragment (scFv) that neutralizes the biological activity of human interferonγ. Mol Immunol 1993; 30: 805-812.
92. Orlandi R, Güssow DH, Jones PT, and Winter G. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc Natl Acad Sci USA 1989; 86: 3833-3837.
93. Ward ES, Güssow D, Griffiths AD, Jones FT, Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia cod'. Nature 1989; 341: 544-546.
94. Froyen G, Hendrix D, Ronsse I, Fiten P, Martens E, Billiau A. Effect of VH and VL consensus sequence specific primers on the binding and neutralizing potential of a single-chain Fv directed towards HuIFNγ. Mol Immunol 1995; 32:515-521.
95. Kwok AYC, Zu X, Yang C, Alfa MJ, Jay FT. Human interferonγ has three domains associated with its antiviral function: a neutralizing epitope typing scheme for human interferonγ. Immunol 1993; 78: 131-137.
96. Ziai MR, Imberti L, Kobayashi M, Perussia B, Trinchieri G, Ferrone S. Distinct functional domains on the recombinant human immune Interferon molecule. Cancer Res 1986; 46: 6187-6190.
97. Van Damme J, Proost P, Put W, Arens S, Lenaerts J-P, Conings R, Opdenakker G, Heremans H, Billiau A. Induction of monocyte chemotactic proteins MCP-1 and MCP-2 in human flbroblasts and leukocytes by cytokines and cytokine inducers: Chemical synthesis of MCP-2 and development of a specific RIA. J Immunol 1994; 152: 5495-5502.
98. Lundell DJ, Narula SK. Structural elements required for receptor recognition of human interferon-gamma. Pharmac Ther 1994; 64: 1-21.
99. Klein B, Brailly H. Cytokine-binding proteins: stimulating antagonists. Immunol Today 1995; 16: 216-220.
100. Adair JR. Engineering antibodies for therapy. Immunol Rev 1992; 130: 5-40.
101. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted interferonγ genes. Science 1993; 259: 17391742.
102. Huang S, Hendriks W, Althage A, Hemmi S, Bluethmann H, Kami jo R, Vilcek J, Zinkemagel RM, Aguet M. Immune response in mice that lack the interferonγ receptor. Science 1993; 259: 1742-1745.
103. Address for correspondence: University of Leuven, Rega Institute for Medical Research, Minderbroedersstraat 10, Leuven, Belgium